State Street SPDR S&P Pharmaceuticals ETF
XPH
74 hedge funds and large institutions have $141M invested in State Street SPDR S&P Pharmaceuticals ETF in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 25 closing their positions.
197% more call options, than puts
Call options by funds: $883K | Put options by funds: $297K
5.21% more ownership
Funds ownership: 51.18% → 56.39% (+5.2%)
12% less funds holding
Funds holding: 84 → 74 (-10)
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
31% less capital invested
Capital invested by funds: $205M → $141M (-$63.1M)
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$13.1M |
| 2 |
JP Morgan Chase
New York
|
+$5.08M |
| 3 |
Barclays
London,
United Kingdom
|
+$2.02M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.56M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$15.9M |
| 2 |
Lazard Asset Management
New York
|
-$7.54M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.73M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$2.9M |
| 5 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
-$2.6M |
XPH Hedge Fund Activity: Q4 2018 in Review
74 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2018, worth a combined $141M — down 31% from $205M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of XPH and 15 opened new positions — a net loss of 10 holders — while 21 trimmed existing stakes and 18 added.
The largest buyer was Goldman Sachs, adding an estimated $13.1M. The largest seller was HighTower Advisors, exiting entirely with an estimated $15.9M sold.
- 74 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2018, down from 84 in Q3 2018.
- Funds reported $141M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2018, down 31% quarter-over-quarter.
- 15 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2018 and 25 closed out, a net change of -10 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2018 was Goldman Sachs, an estimated $13.1M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2018 was HighTower Advisors, an estimated $15.9M sold.
Based on aggregated 13F filings for Q4 2018.